Genflow Biosciences reaffirms commitment to new markets
London, UK
|
May 16, 2023 03:00 AM Eastern Daylight Time
Dr. Eric Leire, CEO of Genflow Biosciences PLC, recently announced exciting developments in the company's fight against nonalcoholic steatohepatitis (NASH), a liver disease that affects millions of people worldwide. Significant progress has been made in its pre-clinical program, targeting fat deposition, fibrosis, and liver cancer associated with NASH.
The company has strengthened its Scientific Advisory Board with the addition of Professor Dr Sven Franque, an expert in NASH and regulatory authorities. Furthermore, Genflow has promoted Tamara Joseph as chairperson, reflecting their commitment to diversity and expanding their presence in the US market. They have also applied to trade on the OTC QB market, and Dr. Leire plans to increase their presence in the US. These advancements highlight Genflow's dedication to addressing the unmet need in NASH treatment.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
